{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DTG+Tablet&page=3", "query": { "intervention": "DTG Tablet", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 98, "total_pages": 10, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DTG+Tablet&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=DTG+Tablet&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T10:02:55.491Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04600687", "title": "B/F/TAF Ease of Swallowability Trial", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Placebo tablets", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Henry Ford Health System", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 50, "start_date": "2018-11-06", "completion_date": "2020-10-10", "has_results": false, "last_update_posted_date": "2020-10-23", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT04600687" }, { "nct_id": "NCT00942136", "title": "GSK1349572 Proton Pump Inhibitor Drug Interaction and Supratherapeutic Dose Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteer" ], "interventions": [ { "name": "GSK1349572", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2009-07", "completion_date": "2009-09", "has_results": false, "last_update_posted_date": "2009-10-09", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00942136" }, { "nct_id": "NCT03016533", "title": "Dolutegravir Study in HIV-1 Participants Completing IMPAACT Studies P1093 and P2019", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Dolutegravir film-coated tablets", "type": "DRUG" }, { "name": "Dolutegravir film-coated dispersible tablets", "type": "DRUG" }, { "name": "ABC/DTG/3TC immediate release tablets", "type": "DRUG" }, { "name": "ABC/DTG/3TC film-coated dispersible tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "25 Years", "sex": "ALL", "summary": "Up to 25 Years" }, "enrollment_count": 100, "start_date": "2017-06-06", "completion_date": "2024-12-24", "has_results": true, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 3, "location_summary": "Los Angeles, California • Fort Lauderdale, Florida • Memphis, Tennessee", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03016533" }, { "nct_id": "NCT02607930", "title": "Study to Evaluate the Safety and Efficacy of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in Human Immunodeficiency Virus-1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "ABC/DTG/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" }, { "name": "ABC/DTG/3TC Placebo", "type": "DRUG" }, { "name": "B/F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 631, "start_date": "2015-11-13", "completion_date": "2021-07-02", "has_results": true, "last_update_posted_date": "2022-03-02", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 78, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 57 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02607930" }, { "nct_id": "NCT03816696", "title": "Study to Evaluate the Pharmacokinetic (PK) Interactions Between GSK3640254 and Dolutegravir (DTG)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "GSK3640254", "type": "DRUG" }, { "name": "DTG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-01-23", "completion_date": "2019-04-10", "has_results": true, "last_update_posted_date": "2020-03-19", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03816696" }, { "nct_id": "NCT02105987", "title": "A Phase IIIb Study of the Safety, Efficacy, and Tolerability of Switching to a Fixed-dose Combination of Abacavir/Dolutegravir/ Lamivudine From Current Antiretroviral Regimen", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "ABC/DTG/3TC FDC", "type": "DRUG" }, { "name": "Ongoing cART regimen", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 555, "start_date": "2014-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-01-04", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 87, "location_summary": "Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 64 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Long Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02105987" }, { "nct_id": "NCT03984838", "title": "Study to Evaluate Pharmacokinetics, Safety and Tolerability of Dolutegravir and Rilpivirine (JULUCA™) 50 Milligram (mg)/25 mg Tablets in Healthy Subjects of Japanese Descent", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 16, "start_date": "2019-06-17", "completion_date": "2019-08-13", "has_results": true, "last_update_posted_date": "2020-07-14", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 1, "location_summary": "Glendale, California", "locations": [ { "city": "Glendale", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03984838" }, { "nct_id": "NCT04302896", "title": "Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Medication Adherence", "HIV" ], "interventions": [ { "name": "dolutegravir oral tablet 50mg", "type": "DRUG" }, { "name": "emtricitabine/tenofovir alafenamide oral tablet 200mg/25mg", "type": "DRUG" }, { "name": "tenofovir disoproxil fumarate oral tablet 300mg", "type": "DRUG" }, { "name": "lamivudine oral tablet 300mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rhonda Brand", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-08-31", "completion_date": "2021-09-30", "has_results": false, "last_update_posted_date": "2022-03-03", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04302896" }, { "nct_id": "NCT03819114", "title": "Pharmacokinetic Study to Evaluate Double-Dose Levonorgestrel Emergency Contraception in Combination With Efavirenz-Based Antiretroviral Therapy or Rifampicin-Containing Anti-Tuberculosis Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Tuberculosis" ], "interventions": [ { "name": "Levonorgestrel (LNG)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "FEMALE", "summary": "16 Years and older · Female only" }, "enrollment_count": 122, "start_date": "2019-05-06", "completion_date": "2020-11-30", "has_results": true, "last_update_posted_date": "2021-12-27", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 7, "location_summary": "Chicago, Illinois • New York, New York • Chapel Hill, North Carolina + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Chicago", "state": "Illinois" }, { "city": "New York", "state": "New York" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03819114" }, { "nct_id": "NCT02605954", "title": "Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "E/C/F/TAF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "Third Antiretroviral Agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 275, "start_date": "2015-11-18", "completion_date": "2018-01-24", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-10-17T10:02:55.491Z", "location_count": 12, "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Fort Lauderdale", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02605954" } ] }